Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combined Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC in PD-L1 Positive Patients (CPS≥1)

NCT05433116 is registered in ClinicalTrials.gov with Universität des Saarlandes as lead sponsor.

NCT NCT05433116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05433116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combined Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC in PD-L1 Positive Patients (CPS≥1)
Lead sponsor
Universität des Saarlandes
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 25, 2023
Completion date
January 31, 2027
Enrollment
50 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma